Tylenol manufacturer Kenvue Brands LLC sent a letter to the Food and Drug Administration, criticizing demands that the drug's label be changed to reflect greater safety warnings.
The FDA announced the first round of pharmaceuticals that will receive expedited reviews under the Commissioner’s National Priority Voucher (CNPV) pilot program.
